Abstract
Background Data on viral factors causing pediatric disease and guidance for pediatric-specific considerations have lagged behind adults throughout the COVID-19 pandemic. As COVID-19 infections and deaths increase in the pediatric population, characterization of SARS-CoV-2 viral dynamics in children would enable data-driven public health guidance.
Methods Nasal swabs collected from children with COVID-19 were analyzed. Viral load was quantified by RT-PCR; viral culture was assessed by direct observation of cytopathic effects and semiquantitative viral titers. Correlations with age or symptom duration were analyzed. SARS-CoV-2 whole genome amplification was compared with contemporaneous Massachusetts sequences to assess for clustering patterns.
Results Ninety-seven children with COVID-19 (median age 10 years, range 2 weeks-22 years) were included in this study. Age did not impact SARS-CoV-2 viral load in nasal secretions: children of all ages were equally likely to carry live, replicating virus. Children within the first five days of illness had higher viral loads and rates of culture positivity, and viral load in hospitalized children (n=30) did not differ from hospitalized adults (n=21) with similar duration of symptoms. While pediatric SARS-CoV-2 sequences were representative of those in the community, novel variants were identified.
Conclusions Children can carry high quantities of live, replicating virus, creating a potential reservoir for transmission and evolution of genetic variants. As guidance around social distancing and masking evolves following vaccine uptake in older populations, a clear understanding of SARS-CoV-2 infection dynamics in children is critical for rational development of public health policies and vaccination strategies to mitigate the impact of COVID-19.
Key points
- Infants, children and adolescents are equally capable of carrying live, replicating SARS-CoV-2 in their nasal secretions.
- Respiratory secretions of infants, children and adolescents with COVID-19 are most infectious before symptoms develop and during the first five days of illness.
- Children can harbor SARS-CoV-2 variants that could have implications for disease severity and vaccine efficacy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The viral culture work was performed in the Ragon Institute BSL3 core, which is supported in part by the NIH-funded Harvard University Center for AIDS Research (P30 AI060354). This research was supported by the National Heart, Lung, and Blood Institute (5K08HL143183 to LMY), the Department of Pediatrics at Massachusetts General Hospital for Children (to LMY), the Massachusetts Consortium for Pathogen Readiness and a gift from Mark and Lisa Schwartz (to JZL).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Infants, children and adolescents <22 years of age presenting to Massachusetts General Hospital urgent care clinics or the hospital with COVID-19 as determined by PCR testing of nasal specimens (4/2020-4/2021) were offered enrollment in the Institutional Review Board-approved MGH Pediatric COVID-19 Biorepository (IRB # 2020P000955). Nasal samples from adults hospitalized with acute COVID-19 (4/2020-8/2020; enrolled in Institutional Review Board-approved MGH COVID-19 Biorepository, IRB # 2020P000804) were used for comparison of viral load. Demographic and clinical factors were recorded through a combination of manual charts reviews and data extraction from electronic health records (EHR), then collected in a REDCap database [15] through the Partners Electronic Health Record Registry of Pediatric COVID-19 Disease (IRB # 2020P003588).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon request once manuscript is published.
